Asgpr-binding compounds for the degradation of extracellular proteins
US-2024424108-A1 · Dec 26, 2024 · US
Quinazoline derivatives, compositions, and uses related thereto
US9868728B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9868728-B2 |
| Application number | US-201113876869-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 25, 2011 |
| Priority date | Oct 29, 2010 |
| Publication date | Jan 16, 2018 |
| Grant date | Jan 16, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to quinazoline derivatives, compositions, and methods related thereto. In certain embodiments, the invention relates to inhibitors of NADPH-oxidase.
First claim
Opening claim text (preview).
The invention claimed is: 1. A pharmaceutical formulation comprising 6-chloro-3-(3-(dimethylamino)propyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one or salt thereof and a pharmaceutically acceptable carrier. 2. The pharmaceutical formulation of claim 1 in the form of a tablet, soft or hard gelatin or non-gelatin capsule, or caplet. 3. The pharmaceutical formulation of claim 1 wherein the pharmaceutically acceptable carrier is selected from dicalcium phosphate dihydrate, calcium sulfate, sucrose, glucose, dextrose, lactose, sorbitol, dextrose, cellulose, starch, gelatin, silicone dioxide, titanium oxide, magnesium aluminum silicate, magnesium stearate, calcium stearate, stearic acid, glycerol behenate, polyethylene glycol, talc, mineral oil, and an acrylic polymer. 4. The pharmaceutical formulation of claim 1 wherein the pharmaceutically acceptable carrier is a lubricant, surfactant, or enteric coating.
Assignees
Inventors
Classifications
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Anti-Parkinson drugs · CPC title
Drugs for disorders of the respiratory system · CPC title
Antiasthmatics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9868728B2 cover?
- The invention relates to quinazoline derivatives, compositions, and methods related thereto. In certain embodiments, the invention relates to inhibitors of NADPH-oxidase.
- Who is the assignee on this patent?
- Lambeth John David, Ganesh Thota, Smith Susan M, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification C07D417/12. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).